Our news

  • The Cochrane Urology Review Group (CURG) currently holds a portfolio of protocols and reviews dedicated to the diagnosis, prevention, treatment, and rehabilitation of:·         Benign and malignant prostate conditions, including benign prostatic hyperplasia, prostate cancer, and prostatitis.·  ...
    November 25 2020
  • Lower urinary tract symptoms caused by benign prostatic obstruction (LUTS/BPO) represents one of the most common clinical complaints in men. Physical activity might represent a viable first-line intervention for treating LUTS/BPO. The objective this study was to assess the effects of physical activity for lower urinary tract symptoms caused by...
    April 6 2019
  • We at Cochrane Urology would like to thank Drive for Men’s Health™ for their generous donation—and congratulate them on another successful year!The purpose of the Drive for Men’s Health™ marathon is to increase awareness of men’s-health issues and to encourage men to make their health a priority. In 2019, Drive for Men’s Health™ went...
    March 13 2019
  • New, minimally invasive surgeries have emerged as alternatives to transurethral resection of the prostate (TURP) for the management of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Aquablation is a novel, minimally invasive, water-based therapy, combining image guidance and robotics for the removal of...
    February 13 2019
  • This intensive two-day workshop, co-hosted by Cochrane Eyes and Vision U.S. satellite and the Meta-Research Innovation Center at Stanford (METRICS), will guide participants through thesteps of developing a systematic review using the latest Cochrane methodology. Led by a team who has extensive expertise in conducting systematic reviews and in...
    February 8 2019
  • Ureteroscopy combined with laser stone fragmentation and basketing is a common approach for managing renal and ureteral stones. This procedure is associated with some degree of ureteral trauma. Ureteral trauma may lead to swelling, ureteral obstruction, and flank pain and may require subsequent interventions such as hospital admission or...
    February 6 2019
  • Benign prostatic hyperplasia (BPH) refers to nonmalignant enlargement of the prostate gland that may cause bothersome lower urinary tract symptoms (LUTS). Alpha-blockers (ABs) and 5-alpha reductase inhibitors (5-ARIs) are the mainstay of medical treatment. Recently, phosphodiesterase inhibitors (PDEIs) that so far have been used mainly to treat...
    November 16 2018
  • Despite efforts to preserve the neurovascular bundles with nerve-sparing surgery, erectile dysfunction remains common following radical prostatectomy. Postoperative penile rehabilitation seeks to restore erectile function but results have been conflicting.Penile rehabilitation for postprostatectomy erectile dysfunctionAuthors: Philippou YA, Jung...
    October 23 2018
  • There has been considerable development in the treatment of advanced prostate cancer over the last decade. A number of agents, including docetaxel, cabazitaxel, abiraterone acetate, enzalutamide and sipuleucel-T, have been reported to improve outcomes in men with castration-resistant disease and their use is being explored in hormone-sensitive...
    October 15 2018
  • The use of systemic immunotherapy targets is emerging as an important treatment option for metastatic urothelial carcinoma, particularly for patients who cannot tolerate or who fail cisplatin-based chemotherapy. One such target is the inhibition of the checkpoint protein programmed cell death-1 (PD-1) receptor and its ligand (PD-L1) by monoclonal...
    July 23 2018

Pages

Subscribe to Our news